Daniel A. Mulrooney

Daniel A. Mulrooney

Auto-generated profile, based on publicly available information

Daniel A. Mulrooney

Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2016 in Annals of Internal Medicine
Verified
Journal Article
Closed access
DMDaniel A. Mulrooney
Daniel A. Mulrooney
GAGregory T. Armstrong
Gregory T. Armstrong
SHSujuan Huang
Sujuan Huang
KNKirsten K. Ness
Kirsten K. Ness
MEMatthew Ehrhardt
Matthew Ehrhardt
MHMelissa M. Hudson
Melissa M. Hudson
Information on the presence of cardiac abnormalities among adult survivors of childhood cancer is limited. This large, prospective study evaluated asymptomatic adult survivors of childhood cancer e... Background: Studies of cardiac disease among adult survivors of childhood cancer have generally relied on self-reported or registry-based data. Objective: To systematically assess cardiac outcomes ...

15 January 2020 in BMJ
Verified
Journal Article
Open access
PDF file
DMDaniel A Mulrooney
Daniel A Mulrooney
GHGeehong Hyun
Geehong Hyun
KNKirsten K Ness
Kirsten K Ness
MEMatthew J Ehrhardt
Matthew J Ehrhardt
YYYutaka Yasui
Yutaka Yasui
GAGregory T Armstrong
Gregory T Armstrong
Objective To investigate the impact of modifications to contemporary cancer protocols, which minimize exposures to cardiotoxic treatments and preserve long term health, on serious cardiac outcomes among adult survivors of childhood cancer. Design Retrospective cohort study. Setting 27 institutions participating in the Childhood Cancer Survivor Study. Participants 23 462 five year survivors (6193 (26.4%) treated in the 1970s, 9363 (39.9%) treated in the 1980s, and 7906 (33.6%) treated in the 1990s) of leukemia, brain cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, renal tumors, neuroblastoma, soft tissue sarcomas, and bone sarcomas diagnosed prior to age 21 years between 1 January 1970 and 31 December 1999. Median age at diagnosis was 6.1 years (range 0-20.9) and 27.7 years (8.2-58.3) at last follow-up. A comparison group of 5057 siblings of cancer survivors were also included. Main outcome measures Cumulative incidence and 95% confidence intervals of reported heart failure, coronary artery disease, valvular heart disease, pericardial disease, and arrhythmias by treatment decade. Events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events. Multivariable subdistribution hazard models were used to estimate hazard ratios by decade, and mediation analysis examined risks with and without exposure to cardiotoxic treatments. Results The 20 year cumulative incidence of heart failure (0.69% for those treated in the 1970s, 0.74% for those treated in the 1980s, 0.54% for those treated in the 1990s) and coronary artery disease (0.38%, 0.24%, 0.19%, respectively), decreased in more recent eras (P<0.01), though not for valvular disease (0.06%, 0.06%, 0.05%), pericardial disease (0.04%, 0.02%, 0.03%), or arrhythmias (0.08%, 0.09%, 0.13%). Compared with survivors with a diagnosis in the 1970s, the risk of heart failure, coronary artery disease, and valvular heart disease decreased in the 1980s and 1990s but only significantly for coronary artery disease (hazard ratio 0.65, 95% confidence interval 0.45 to 0.92 and 0.53, 0.36 to 0.77, respectively). The overall risk of coronary artery disease was attenuated by adjustment for cardiac radiation (0.90, 0.78 to 1.05), particularly among survivors of Hodgkin lymphoma (unadjusted for radiation: 0.77, 0.66 to 0.89; adjusted for radiation: 0.87, 0.69 to 1.10). Conclusions Historical reductions in exposure to cardiac radiation have been associated with a reduced risk of coronary artery disease among adult survivors of childhood cancer. Additional follow-up is needed to investigate risk reductions for other cardiac outcomes. Trial registration ClinicalTrials.gov NCT01120353.

1 June 2019 in The Lancet Haematology
Verified
Journal Article
Closed access
DMDaniel A Mulrooney
Daniel A Mulrooney
GHGeehong Hyun
Geehong Hyun
KNKirsten K Ness
Kirsten K Ness
NBNickhill Bhakta
Nickhill Bhakta
CPChing-Hon Pui
Ching-Hon Pui
MHMelissa M Hudson
Melissa M Hudson

1 April 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SSSonali M. Smith
Sonali M. Smith
KWKerri Wachter
Kerri Wachter
HBHoward A. Burris
Howard A. Burris
RSRichard L. Schilsky
Richard L. Schilsky
DGDaniel James George
Daniel James George
RURobert Uzzo
Robert Uzzo

15 April 2025 in Circulation
Verified
Journal Article
Closed access
TRThomas D. Ryan
Thomas D. Ryan
JBJames E. Bates
James E. Bates
KKKaren E. Kinahan
Karen E. Kinahan
KLKasey J. Leger
Kasey J. Leger
DMDaniel A. Mulrooney
Daniel A. Mulrooney
OCon behalf of the Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
on behalf of the Pediatric Heart Failure & Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Anthracycline chemotherapy and chest-directed radiotherapy are the most well-studied cardiotoxic therapies, and dose reduction, use of cardioprotection for anthracyclines, and modern radiotherapy approaches have contributed to improved cardiovascular outcomes for survivors. Newer treatments such as small-molecule inhibitors, antibody-based cytotoxic therapy, and immunotherapy have expanded options for previously difficult-to-treat cancers but have also revealed new cardiotoxic profiles. Application of effective surveillance strategies in patients with cancer and survivors has been a focus of practitioners and researchers, whereas the prevention and treatment of extant cardiovascular disease is still developing. Incorporation of new strategies in an equitable manner and appropriate transition from pediatric to adult care will greatly influence long-term health-related outcomes in the growing population of childhood cancer survivors at risk for cardiovascular disease.

8 February 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KHKohei Hagiwara
Kohei Hagiwara
SNSivaraman Natarajan
Sivaraman Natarajan
ZWZhaoming Wang
Zhaoming Wang
HZHaseeb Zubair
Haseeb Zubair
HMHeather L. Mulder
Heather L. Mulder
JZJinghui Zhang
Jinghui Zhang
We present the first comprehensive investigation of clonal hematopoiesis (CH) in 2,860 long-term survivors of pediatric cancer with a median follow-up time of 23.5 years. Deep sequencing over 39 CH-related genes reveals mutations in 15% of the survivors, significantly higher than the 8.5% in 324 community controls. CH in survivors is associated with exposures to alkylating agents, radiation, and bleomycin. Therapy-related CH shows significant enrichment in STAT3, characterized as a CH gene specific to survivors of Hodgkin lymphoma, and TP53. Single-cell profiling of peripheral blood samples revealed STAT3 mutations predominantly present in T cells and contributed by SBS25, a mutational signature associated with procarbazine exposure. Serial sample tracking reveals that larger clone size is a predictor for future expansion of age-related CH clones, whereas therapy-related CH remains stable decades after treatment. These data depict the distinct dynamics of these CH subtypes and support the need for longitudinal monitoring to determine the potential contribution to late effects. Significance: This first comprehensive CH analysis in long-term survivors of pediatric cancer presents the elevated prevalence and therapy exposures/diagnostic spectrum associated with CH. Due to the contrasting dynamics of clonal expansion for age-related versus therapy-related CH, longitudinal monitoring is recommended to ascertain the long-term effects of therapy-induced CH in pediatric cancer survivors. See related commentary by Collord and Behjati, p. 811. This article is highlighted in the In This Issue feature, p. 799